Literature DB >> 6276164

Proopiolipomelanocortin peptides in normal pituitary, pituitary tumor, and plasma of normal and Cushing's horses.

M G Wilson, W E Nicholson, M A Holscher, B J Sherrell, C D Mount, D N Orth.   

Abstract

Using RIAs for six regions within proopiolipomelanocortin (proOLMC), gel filtration, and electrophoresis, we studied pituitary peptides in a normal horse and one with Cushing's disease caused by a pars intermedia adenoma. Almost all immunoreactive (IR) ACTH (78%) was 4,500 mol wt (4.5K) ACTH in normal pars distalis, but it was almost 100% corticotropin-like intermediate lobe peptide (CLIP) in normal pars intermedia. alpha MSH and beta MSH were found mainly in pars intermedia: equal concentrations of the beta MSH precursors, beta-lipotropin (beta LPH) and gamma LPH, were found in pars distalis. Most IR-beta-endorphin (IR-beta END) was found as beta END in pars intermedia, but roughly equal concentrations of beta END and its precursor, beta LPH, were found in pars distalis. A 33K molecule containing IR-ACTH, IR-gamma 3MSH, and IR-beta END, presumed to be proOLMC, and a variety of 15-27K presumed biosynthetic intermediates were found in both normal pars distalis and pars intermedia. The pars intermedia adenoma causing Cushing's syndrome contained high IR-peptide concentrations. Several differences in precursors were noted, including the presence of three larger presumed precursors (38.5K, 47K, and 63K) that had both ACTH and beta END immunoreactivities and both deletions and additions of 15-27K intermediates. The Cushing's horse's plasma peptides reflected tumor concentrations; 4.5K ACTH was modestly elevated, but the concentrations of CLIP, alpha MSH, beta MSH, gamma LPH, and beta END were dramatically increased. About 20% of plasma IR-ACTH and 5% of IR-beta MSH and IR-beta END were found as high molecular weight forms. Normal processing of horse proOLMC appears to be similar to that in other species, but may be altered in pars intermedia tumors of horses with Cushing's disease, the plasma of which contains disproportionately increased concentrations of pars intermedia proOLMC peptides.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6276164     DOI: 10.1210/endo-110-3-941

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  4 in total

1.  Effect of synthetic ovine corticotropin-releasing factor. Dose response of plasma adrenocorticotropin and cortisol.

Authors:  D N Orth; R V Jackson; G S DeCherney; C R DeBold; A N Alexander; D P Island; J Rivier; C Rivier; J Spiess; W Vale
Journal:  J Clin Invest       Date:  1983-03       Impact factor: 14.808

2.  Comparison of two methods for measurement of equine adrenocorticotropin.

Authors:  Heidi E Banse; Nichol Schultz; Molly McCue; Ray Geor; Dianne McFarlane
Journal:  J Vet Diagn Invest       Date:  2017-12-28       Impact factor: 1.279

3.  Human plasma epidermal growth factor/beta-urogastrone is associated with blood platelets.

Authors:  Y Oka; D N Orth
Journal:  J Clin Invest       Date:  1983-07       Impact factor: 14.808

4.  Pituitary Pars Intermedia Dysfunction and Metabolic Syndrome in Donkeys.

Authors:  Heidrun Gehlen; Bianca Schwarz; Claus Bartmann; Jennifer Gernhardt; Sabita D Stöckle
Journal:  Animals (Basel)       Date:  2020-12-08       Impact factor: 2.752

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.